MOs derived from iPSCs carrying the known PD risk mutation LRRK2-G2019S have been shown to demonstrate aberrant accumulation and deposition of α-synuclein, which was successfully ameliorated by LRRK2 kinase inhibitor treatment [123]. The gene discussed is LRRK2; the disease is Parkinson disease.